Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey

Basit Öğe Kaydı
dc.authoridHamuryudan, Vedat / 0000-0001-6625-1652
dc.authoridinanc, murat / 0000-0002-6376-5583
dc.authoridAkkoc, Nurullah / 0000-0002-3718-171X
dc.authorwosidHamuryudan, Vedat / AAA-1100-2020
dc.authorwosidErtenli, Ihsan / AAV-7175-2021
dc.authorwosidinanc, murat / I-3444-2012
dc.authorwosidAkkoc, Nurullah / D-9870-2011
dc.authorwosidDireskeneli, Haner / AAS-5508-2020
dc.contributor.authorHamuryudan, V.
dc.contributor.authorDireskeneli, H.
dc.contributor.authorErtenli, I.
dc.contributor.authorInanc, M.
dc.contributor.authorKaraaslan, Y.
dc.contributor.authorOksel, F.
dc.contributor.authorAkkoc, N.
dc.date.accessioned2021-11-01T14:58:21Z
dc.date.available2021-11-01T14:58:21Z
dc.date.issued2016
dc.department[Belirlenecek]
dc.description.abstractObjective To estimate the annual cost of rheumatoid arthritis (RA) in Turkey by obtaining real-world data directly from patients. Methods In this cross-sectional study, RA patients from the rheumatology outpatient clinics of 10 university hospitals were interviewed with a standardised questionnaire on RA-related healthcare care costs. Results The study included 689 RA patients (565 females) with a mean age of 51.2 +/- 13.2 years and mean disease duration of 9.4 +/- 7.8 years. The mean scores of the Routine Assessment of Patient Index Data 3 and the Health Assessment Questionnaire Disability Index (5.08 +/- 2.34 and 1.08 +/- 0.68, respectively) indicated moderate disease activity and severity for the whole group. One-third of the patients were on biologic agents and 12% had co-morbid conditions. The mean number of annual outpatient visits was 11.7 +/- 9.6 per patient. Of the patients, 15% required hospitalisation and 4% underwent surgery. The mean annual direct cost was 4,954 (median, 1,805), whereas the mean annual indirect cost was 2,802 (median, 608). Pharmacy costs accounted for the highest expenditure (mean, 2,777; median, 791), followed by the RA-related consultations and expenses (mean, 1,600; median, 696). Conclusion RA has a substantial economic burden in Turkey, direct costs being higher than indirect costs. Although both direct and indirect costs are lower in Turkey than in Europe with respect to nominal Euro terms, they are higher from the perspectives of purchasing power parity and gross domestic product. Early diagnosis and treatment of RA may positively affect the national economy considering the positive correlation between health care utilisations and increased cost with disease severity.
dc.identifier.endpage1037en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue6en_US
dc.identifier.pmid27749224
dc.identifier.startpage1033en_US
dc.identifier.urihttps://hdl.handle.net/11491/6606
dc.identifier.volume34en_US
dc.identifier.wosWOS:000391165100011
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical And Experimental Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectrheumatoid arthritisen_US
dc.subjecthealthcare costen_US
dc.subjectTurkeyen_US
dc.subjecteconomic burden of diseaseen_US
dc.titleDirect and indirect healthcare costs of rheumatoid arthritis patients in Turkey
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize